South Korea
· Delayed Price · Currency is KRW Wonbiogen Statistics
Total Valuation
Wonbiogen has a market cap or net worth of KRW 37.67 billion. The enterprise value is 25.86 billion.
| Market Cap | 37.67B |
| Enterprise Value | 25.86B |
Important Dates
The last earnings date was Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Wonbiogen has 7.09 million shares outstanding. The number of shares has decreased by -6.02% in one year.
| Current Share Class | 7.09M |
| Shares Outstanding | 7.09M |
| Shares Change (YoY) | -6.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 32.42% |
| Owned by Institutions (%) | n/a |
| Float | 4.79M |
Valuation Ratios
The trailing PE ratio is 6.47.
| PE Ratio | 6.47 |
| Forward PE | n/a |
| PS Ratio | 1.18 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | 5.36 |
| P/OCF Ratio | 4.81 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.16, with an EV/FCF ratio of 3.68.
| EV / Earnings | 4.43 |
| EV / Sales | 0.81 |
| EV / EBITDA | 3.16 |
| EV / EBIT | 3.93 |
| EV / FCF | 3.68 |
Financial Position
The company has a current ratio of 5.78, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.78 |
| Quick Ratio | 4.19 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | 0.12 |
| Interest Coverage | 131.66 |
Financial Efficiency
Return on equity (ROE) is 14.56% and return on invested capital (ROIC) is 10.05%.
| Return on Equity (ROE) | 14.56% |
| Return on Assets (ROA) | 9.28% |
| Return on Invested Capital (ROIC) | 10.05% |
| Return on Capital Employed (ROCE) | 16.51% |
| Revenue Per Employee | 421.38M |
| Profits Per Employee | 76.84M |
| Employee Count | 76 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 2.69 |
Taxes
In the past 12 months, Wonbiogen has paid 1.05 billion in taxes.
| Income Tax | 1.05B |
| Effective Tax Rate | 16.30% |
Stock Price Statistics
The stock price has increased by +244.71% in the last 52 weeks. The beta is 0.64, so Wonbiogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | +244.71% |
| 50-Day Moving Average | 5,472.00 |
| 200-Day Moving Average | 2,410.38 |
| Relative Strength Index (RSI) | 48.87 |
| Average Volume (20 Days) | 16,324 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Wonbiogen had revenue of KRW 32.02 billion and earned 5.84 billion in profits. Earnings per share was 821.01.
| Revenue | 32.02B |
| Gross Profit | 15.20B |
| Operating Income | 6.54B |
| Pretax Income | 6.42B |
| Net Income | 5.84B |
| EBITDA | 8.14B |
| EBIT | 6.54B |
| Earnings Per Share (EPS) | 821.01 |
Balance Sheet
The company has 12.56 billion in cash and 835.09 million in debt, giving a net cash position of 11.72 billion or 1,652.10 per share.
| Cash & Cash Equivalents | 12.56B |
| Total Debt | 835.09M |
| Net Cash | 11.72B |
| Net Cash Per Share | 1,652.10 |
| Equity (Book Value) | 39.25B |
| Book Value Per Share | 5,539.39 |
| Working Capital | 19.99B |
Cash Flow
In the last 12 months, operating cash flow was 7.82 billion and capital expenditures -798.06 million, giving a free cash flow of 7.03 billion.
| Operating Cash Flow | 7.82B |
| Capital Expenditures | -798.06M |
| Free Cash Flow | 7.03B |
| FCF Per Share | 990.43 |
Margins
Gross margin is 47.48%, with operating and profit margins of 20.42% and 18.23%.
| Gross Margin | 47.48% |
| Operating Margin | 20.42% |
| Pretax Margin | 20.05% |
| Profit Margin | 18.23% |
| EBITDA Margin | 25.41% |
| EBIT Margin | 20.42% |
| FCF Margin | 21.94% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.88%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.88% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 12.14% |
| Buyback Yield | 6.02% |
| Shareholder Yield | 7.91% |
| Earnings Yield | 15.50% |
| FCF Yield | 18.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Wonbiogen has an Altman Z-Score of 8.72 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.72 |
| Piotroski F-Score | 7 |